Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians

被引:8
作者
Samimi, Goli [1 ]
Heckman-Stoddard, Brandy M. [1 ]
Holmberg, Christine [2 ]
Tennant, Bethany [3 ]
Sheppard, Bonny Bloodgood [3 ]
Coa, Kisha, I [3 ]
Kay, Shelley S. [3 ]
Ford, Leslie G. [1 ]
Szabo, Eva [1 ]
Minasian, Lori M. [1 ]
机构
[1] NCI, Div Canc Prevent, Bethesda, MD 20872 USA
[2] Brandenburg Med Sch Theodor Fontane, Inst Social Med & Epidemiol, Brandenburg, Havel, Germany
[3] ICF, Fairfax, VA USA
关键词
INCREASE RECOMMENDATION; COLORECTAL CANCERS; SYSTEMATIC REVIEWS; DECISION-MAKING; FOLLOW-UP; PREVENTION; TAMOXIFEN; RALOXIFENE; CHEMOPREVENTION; REDUCTION;
D O I
10.1158/1940-6207.CAPR-20-0407
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As clinical guidelines for cancer prevention refer individuals to primary care physicians (PCP) for risk assessment and clinical management, PCPs may be expected to play an increasing role in cancer prevention. It is crucial that PCPs are adequately supported to assess an individual's cancer risk and make appropriate recommendations. The objective of this study is to assess use, familiarity, attitude, and behaviors of PCPs regarding breast and ovarian cancer risk and prevention, to better understand the factors that influence their prescribing behaviors. We conducted a cross-sectional, web-based survey of PCPs in the United States, recruited from an opt-in healthcare provider panel. Invitations were sent in batches until the target sample size of 750 respondents (250 each for obstetrics/gynecology, internal medicine, and family medicine) was met. Self-reported use of breast/ovarian cancer risk assessments was low (34.7%-59.2%) compared with discussion of cancer family history (96.9%), breast exams (87.1%), and mammograms (92.8%). Although most respondents (48.0%-66.8%) were familiar with cancer prevention interventions, respondents who reported to be less familiar were more likely to report cautious attitudes. When presented with hypothetical cases depicting patients at different breast/ovarian cancer risks, up to 34.0% of respondents did not select any of the clinically recommended course(s) of action. This survey suggests that PCP use of breast/ovarian cancer risk assessment tools and ability to translate the perceived risks to clinical actions is variable. Improving implementation of cancer risk assessment and clinical management guidelines within primary care may be necessary to improve the appropriate prescribing of cancer prevention interventions. Prevention Relevance: Primary care physicians are becoming more involved in cancer prevention management, so it is important that cancer risk assessment and medical society guideline recommendations for cancer prevention are better integrated into primary care to improve appropriate prescribing of cancer prevention interventions and help reduce cancer risk.
引用
收藏
页码:185 / 194
页数:10
相关论文
共 48 条
  • [1] [Anonymous], 2017, Obstet Gynecol, V130, pe110, DOI 10.1097/AOG.0000000000002296
  • [2] [Anonymous], 2003, FULFILLING POTENTIAL
  • [3] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [4] Barriers to the Use of Breast Cancer Risk Reduction Therapies
    Bambhroliya, Arvind
    Chavez-MacGregor, Mariana
    Brewster, Abenaa M.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (07): : 927 - 935
  • [5] Intervention to Increase Recommendation and Delivery of Screening for Breast, Cervical, and Colorectal Cancers by Healthcare Providers A Systematic Review of Provider Reminders
    Baron, Roy C.
    Melillo, Stephanie
    Rimer, Barbara K.
    Coates, Ralph J.
    Kerner, Jon
    Habarta, Nancy
    Chattopadhyay, Sajal
    Sabatino, Susan A.
    Elder, Randy
    Leeks, Kimberly Jackson
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2010, 38 (01) : 110 - 117
  • [6] Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
    Barrett-Connor, Elizabeth
    Mosca, Lori
    Collins, Peter
    Geiger, Mary Jane
    Grady, Deborah
    Kornitzer, Marcel
    McNabb, Michelle A.
    Wenger, Nanette K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (02) : 125 - 137
  • [7] Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1
  • [8] Bero LA, 1998, BMJ-BRIT MED J, V317, P465
  • [9] Bevers T, 2020, BREAST CANC RISK RED
  • [10] Breast Cancer Screening and Diagnosis, Version 3.2018
    Bevers, Therese B.
    Helvie, Mark
    Bonaccio, Ermelinda
    Calhoun, Kristine E.
    Daly, Mary B.
    Farrar, William B.
    Garber, Judy E.
    Gray, Richard
    Greenberg, Caprice C.
    Greenup, Rachel
    Hansen, Nora M.
    Harris, Randall E.
    Heerdt, Alexandra S.
    Helsten, Teresa
    Hodgkiss, Linda
    Hoyt, Tamarya L.
    Huff, John G.
    Jacobs, Lisa
    Lehman, Constance Dobbins
    Monsees, Barbara
    Niell, Bethany L.
    Parker, Catherine C.
    Pearlman, Mark
    Philpotts, Liane
    Shepardson, Laura B.
    Smith, Mary Lou
    Stein, Matthew
    Tumyan, Lusine
    Williams, Cheryl
    Bergman, Mary Anne
    Kumar, Rashmi
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (11): : 1362 - 1389